



**Australian Government**  
**Department of Health**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	319828	Metabolism + Sugar Support
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	JSHealth Vitamins Pty Ltd	
<b>Postal Address</b>	17 Kimberley Street, Vaucluse, NSW, 2030 Australia	
<b>ARTG Start Date</b>	8/07/2019	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . Metabolism + Sugar Support

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	8/07/2019
---------------------	-------------------------	-----------------------	-----------

#### Permitted Indications

Antioxidant/Reduce free radicals formed in the body  
Helps reduce/decrease free radical damage to body cells  
Maintain/support energy levels  
Maintain/support body metabolism/metabolic rate  
Maintain/support connective tissue health  
Helps maintain/support healthy blood sugar/glucose  
Maintain/support immune system health  
Maintain/support healthy immune system function  
Aid/assist/helps glucose/sugar/carbohydrate metabolism  
Aid/assist/helps metabolism of (state vitamin/mineral/nutrient)  
Aid/assist/helps synthesis of neurotransmitters  
Maintain/support nervous system health  
Maintain/support skin health

#### Indication Requirements

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

If product is indicated for supplementation, Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.



**Australian Government**  
**Department of Health**  
 Therapeutic Goods Administration

Product presentation must not imply or refer to chronic fatigue syndrome.

Product presentation must not imply or refer to lowering or raising blood sugar/glucose levels from outside of the normal healthy range.

Product presentation must not imply or refer to serious immunological diseases.

**Standard Indications**

No Standard Indications included on Record

**Specific Indications**

No Specific Indications included on Record

**Warnings**

No Warnings included on Record

**Additional Product information**

**Pack Size/Poison information**

Pack Size	Poison Schedule
-----------	-----------------

**Components**

**1 . Formulation 1**

**Dosage Form**                      Tablet, film coated

**Route of Administration**      Oral

**Visual Identification**

**Active Ingredients**

<b>chromic chloride hexahydrate</b>	<b>1.026 mg</b>
Equivalent: chromium	.2 mg
<b>chromium picolinate</b>	<b>.2 mg</b>
Equivalent: chromium	.025 mg
<b>Cinnamomum cassia stem bark Extract dry concentrate</b>	<b>100 mg</b>
Equivalent: Cinnamomum cassia (Dry)	1 g
<b>Garcinia gummi-gutta fruit peel Extract dry concentrate</b>	<b>333 mg</b>
Equivalent: Garcinia gummi-gutta (Dry)	3.333 g
<b>glutamine</b>	<b>50 mg</b>
<b>Gymnema sylvestre leaf Extract dry concentrate</b>	<b>250 mg</b>
Equivalent: Gymnema sylvestre (Dry)	2 g
<b>magnesium citrate</b>	<b>154.33 mg</b>
Equivalent: magnesium	25 mg
<b>magnesium glycinate</b>	<b>177.3 mg</b>
Equivalent: magnesium	25 mg
<b>pyridoxine hydrochloride</b>	<b>9.12 mg</b>
Equivalent: pyridoxine	7.5 mg
<b>zinc citrate dihydrate</b>	<b>31.95 mg</b>
Equivalent: zinc	10 mg

**Other Ingredients (Excipients)**

- calcium hydrogen phosphate dihydrate
- colloidal anhydrous silica
- croscarmellose sodium
- crospovidone
- hypromellose
- iron oxide red
- macrogol 400
- magnesium stearate
- microcrystalline cellulose
- povidone

Public Summary



**Australian Government**

**Department of Health**  
Therapeutic Goods Administration

**pregelatinised maize starch**

---

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary